The 53rd EASD Annual Meeting, held last month, was a great success with more than 15.000 attendants and 1266 abstracts selected. In our last blog post, we provided you with a short overview of some of the interesting novelties presented during the meeting and, today, we are happy to share with you our own contribution to the conference:
Dr. Leona Plum-Mörschel, our Chief Executive Officer from Profil Mainz, gave an oral presentation about the “Efficacy and safety of oral basal insulin: eight-week feasibility study in people with type 2 diabetes” during the session about insulin therapy in type 2 diabetes: novel concepts.
Our Director Project Development/Medical Technology, Dr. Eric Zijlstra, delivered an oral presentation about the “Effect of food intake on the absorption of oral basal insulin” during the improvement in insulin therapy session.
In the same session, our Chief Executive Officer, Dr. Christoph Kapitza gave an oral presentation on “A novel formulation of insulin lispro shows significantly faster absorption and improvement in postprandial glucose excursions versus insulin lispro in patients with type 2 diabetes”.
If you are also interested in the session about Hypoglycemia: treatment and consequences, you can check our ePoster “Dasiglucagon, a novel soluble glucagon analogue, successfully restores blood glucose levels after hypoglycaemia in people with type 1 diabetes” presented by Dr. Tim Heise, our Lead Scientist.
We hope you enjoy our presentations! If you are interested to know more about our expertise you can always arrange a meeting in one of the upcoming conferences or contact our scientists.